Transcranial magnetic stimulation (TMS) is emerging as an innovative treatment for a range of psychiatric disorders, but the current methods for identifying stimulation targets could be improved. In this episode, we are joined by Dr. Balderston, who discusses his pioneering work on a novel targeting optimization approach for TMS treatments that combines whole-brain resting state functional connectivity (rsFC) and electric-field (e-field) modeling.
Dr. Balderston explains how this approach allows for more personalized, symptom-specific TMS targets. He shares results from a proof of concept study involving 91 anxious misery (AM) patients and 25 controls. Using principal component analysis (PCA) regression, his team predicted symptoms from rsFC and estimated the parameter vector for the e-field augmented model.
The potential applications of this method are vast, as it allows for the computation of predicted symptom changes for each site/orientation using the e-field augmented model. Notably, Dr. Balderston's findings suggest that left dlPFC stimulation, tailored to individual brain connectivity, could lead to better outcomes for depression treatment.
Join us as we delve into the intricate world of rsFC, e-field modeling, and the future of individualized TMS therapy with Dr. Balderston.
Keywords: Dr. Balderston, Resting State Functional Connectivity, rsFC, Transcranial Magnetic Stimulation, TMS, Electric-field Modelling, Depression Treatment, Anxious Misery, Individualized Therapy, BA9, Left dlPFC, M1.
https://doi.org/10.1038/s41386-021-01110-6 Transcranial magnetic stimulation (TMS) treatments: using individualized TMS targeting to maximize the therapeutic impact.